![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Phase III study showed Rituxan/MabThera decreased the risk of needing later treatment with chemotherapy...
Roche announced positive data from a Phase III study of Rituxan/MabThera (rituximab) in patients with...
QR Pharma receives FDA clearance to conduct clinical trials with its second novel Alzheimer...
QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced...
Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies
Bayer HealthCare and Regeneron Pharmaceuticals, Inc. announced that in two parallel Phase 3 studies in...
Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl
Abbott Park, Illinois-Reata Pharmaceuticals and Abbott today announced data from a Phase 2b study which...
Novartis discontinues ASA404 clinical trial program and shifts focus to other cancer compounds in...
Novartis announced that the clinical trial program for the investigational cancer treatment ASA404 (vadimezan) will...
Genentech announced the result of Phase II clinical trail of RG7204
Genentech, Inc., a member of the Roche Group announced results from a Phase II clinical...
Sanofi Pasteur’s Dengue Vaccine in Final Stage of Clinical Development
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced that its dengue vaccine is in...
Roche reports promising Phase II results with new targeted approach in advanced melanoma
Roche announced results from a Phase II clinical study of RG7204 PLX4032), an investigational first-in-class...
Genzyme Announces Results of Phase 3 Trial of Clolar in Adult AML
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine)...
Boehringer Ingelheim announced approval for TWYNSTA®. TWYNSTA single pill combination that delivers powerful and...
Boehringer Ingelheim announced today that the European Commission confirmed the positive opinion of the European...